Document Detail


Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
MedLine Citation:
PMID:  16247420     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ovarian failure after allogeneic stem cell transplant (allo-SCT) is an important risk factor for development of osteoporosis. We investigated the effects of various antiresorptive treatments in long-term surviving females with ovarian failure after allo-SCT. A total of 60 women with osteoporosis or osteopenia were divided randomly into four groups of 15 women each. Group 1 was treated with calcium and vitamin D alone, group 2 received the same treatment in combination with hormone replacement therapy (HRT), group 3 received risedronate (35 mg weekly, orally for 1 year) and group 4 zoledronic acid (3 monthly doses of 4 mg (intravenous)). All groups were similar for age, body mass index, underlying disease and time elapsed from transplant. Lumbar and femoral bone mineral density (BMD) were measured at baseline and after 12 months, together with serum osteocalcin and urinary hydroxyproline. At 12 months, a significant decrease in lumbar and femoral BMD was observed in group 1 and a milder decrease in group 2. Risedronate treatment increased significantly lumbar BMD and prevented bone loss at the femoral neck. Zoledronic acid increased significantly both lumbar and femoral BMD. In groups 3 and 4 the hydroxyproline excretion was significantly reduced, while osteocalcin mildly increased only in group 4. In conclusion, bisphosphonate administration is useful to prevent and treat bone demineralization in young adult women after allo-SCT.
Authors:
L Tauchmanovà; G De Simone; T Musella; F Orio; P Ricci; C Nappi; G Lombardi; A Colao; B Rotoli; C Selleri
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Bone marrow transplantation     Volume:  37     ISSN:  0268-3369     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-16     Completed Date:  2006-04-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  81-8     Citation Subset:  IM    
Affiliation:
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Naples, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Anemia, Aplastic / complications,  therapy,  urine
Bone Density / drug effects
Bone Density Conservation Agents / administration & dosage*
Female
Hormone Replacement Therapy / methods
Humans
Hypogonadism* / complications,  urine
Lymphoproliferative Disorders / complications,  therapy,  urine
Osteoporosis / drug therapy*,  etiology,  urine
Stem Cell Transplantation*
Transplantation, Homologous
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.
Next Document:  Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopo...